MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Vertex Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

483.28 -0.22

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

479.62

Макс.

487.51

Ключевые показатели

By Trading Economics

Доход

-132M

913M

Продажи

142M

2.9B

P/E

Средняя по отрасли

30.42

63.778

Прибыль на акцию

3.98

Рентабельность продаж

31.353

Сотрудники

6,100

EBITDA

-99M

1.2B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+2.96% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

5 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

6.8B

127B

Предыдущая цена открытия

483.5

Предыдущая цена закрытия

483.28

Новостные настроения

By Acuity

12%

88%

14 / 386 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 февр. 2025 г., 22:11 UTC

Отчет

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31 янв. 2025 г., 00:19 UTC

Главные движущие силы рынка

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19 дек. 2024 г., 12:25 UTC

Главные движущие силы рынка

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4 нояб. 2024 г., 21:44 UTC

Отчет

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

1 авг. 2024 г., 20:45 UTC

Отчет

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

28 февр. 2025 г., 12:00 UTC

Главные новости

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 февр. 2025 г., 21:12 UTC

Отчет

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11 февр. 2025 г., 14:21 UTC

Отчет

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10 февр. 2025 г., 21:12 UTC

Отчет

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10 февр. 2025 г., 21:12 UTC

Отчет

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10 февр. 2025 г., 21:11 UTC

Отчет

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10 февр. 2025 г., 21:04 UTC

Отчет

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10 февр. 2025 г., 21:04 UTC

Отчет

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10 февр. 2025 г., 21:02 UTC

Отчет

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31 янв. 2025 г., 09:59 UTC

Популярные акции

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4 нояб. 2024 г., 22:21 UTC

Отчет

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4 нояб. 2024 г., 21:25 UTC

Отчет

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4 нояб. 2024 г., 21:03 UTC

Отчет

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

4 нояб. 2024 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX

4 нояб. 2024 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 3Q Net $1.05B >VRTX

4 нояб. 2024 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX

26 сент. 2024 г., 14:20 UTC

Приобретения, слияния, поглощения

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1 авг. 2024 г., 20:30 UTC

Отчет

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1 авг. 2024 г., 20:03 UTC

Отчет

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1 авг. 2024 г., 20:02 UTC

Отчет

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1 авг. 2024 г., 20:02 UTC

Отчет

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

Сравнение c конкурентами

Изменение цены

Vertex Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

2.96% рост

Прогноз на 12 месяцев

Средняя 499.09 USD  2.96%

Максимум 591 USD

Минимум 320 USD

Основано на мнении 27 аналитиков Wall Street, спрогнозировавших целевые цены для Vertex Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

27 ratings

16

Покупка

10

Удержание

1

Продажа

Техническая оценка

By Trading Central

480.95 / 505Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

Bullish Evidence

Настроения

By Acuity

14 / 386Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.